Fujian Provincial Key Laboratory of Translational Cancer Medicine

Fujian, China

Fujian Provincial Key Laboratory of Translational Cancer Medicine

Fujian, China
SEARCH FILTERS
Time filter
Source Type

Li X.,Fujian Medical University | Wang Y.,The Peoples Hospital Of Xishuangbanna Dai Autonomous Prefecture | Tang W.,Jiangsu University | Liu C.,Jiangsu University | And 3 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2017

To address the relationship of ADIPOQ T45G and G276T polymorphisms with polycystic ovary syndrome (PCOS), a meta-analysis was performed in this report. An extensive literature search, selection of eligible publications and extract relevant data were carried out. Sixteen eligible papers with a total number of 2,456 PCOS patients and 4,279 controls met the major including criteria in the pooled analysis on the correlation between ADIPOQ polymorphisms and PCOS. We used crude odds ratios (ORs) with 95% confidence intervals (CIs) to evaluate the strength of relationship. The results demonstrated that there was no evidence for the correlation between ADIPOQ T45G and PCOS even in the subgroup analyses. However, ADIPOQ G276T polymorphism conferred the decreased risk to PCOS in two genetic models: T vs. G (OR, 0.88; 95% CI, 0.78-1.00; P=0.047) and TT+GT vs. GG (OR, 0.80; 95% CI, 0.70-0.93; P=0.003). In a subgroup analysis by ethnicity, the similar findings were also found among Asians in two genetic models: TT vs. GG (OR, 0.55; 95% CI, 0.39-0.78; P=0.001) and TT+GT vs. GG (OR, 0.71; 95% CI, 0.56-0.89; P=0.003). In a subgroup analysis by diagnosis criteria of PCOS, we found that ADIPOQ G276T polymorphism was associated with the decreased risk of PCOS among European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine criteria (ESHRE/ASRM) in three genetic models: T vs. G (OR, 0.80; 95% CI, 0.66-0.99; P=0.036), TT vs. GG (OR, 0.60; 95% CI, 0.40-0.91; P=0.015) and TT+GT vs. GG (OR, 0.71; 95% CI, 0.59-0.85; P<0.001). In summary, our results suggest that ADIPOQ G276T polymorphism was associated with the decreased risk of PCOS, especially in Asians and ESHRE/ASRM of PCOS subgroups. © 2017, E-Century Publishing Corporation. All rights reserved.


Li Z.,Fujian Normal University | Li Z.,Fujian University of Traditional Chinese Medicine | Li C.,Fujian Medical University | Li C.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | And 9 more authors.
Laser Physics Letters | Year: 2014

The aim of this study was to evaluate the potential of applying silver nano-particle based surface-enhanced Raman scattering (SERS) to discriminate different types of human thyroid tissues. SERS measurements were performed on three groups of tissue samples including thyroid cancers (n = 32), nodular goiters (n = 20) and normal thyroid tissues (n = 25). Tentative assignments of the measured tissue SERS spectra suggest interesting cancer specific biomolecular differences. The principal component analysis (PCA) and linear discriminate analysis (LDA) together with the leave-one-out, cross-validated technique yielded diagnostic sensitivities of 92%, 75% and 87.5%; and specificities of 82.6%, 89.4% and 84.4%, respectively, for differentiation among normal, nodular and malignant thyroid tissue samples. This work demonstrates that tissue SERS spectroscopy associated with multivariate analysis diagnostic algorithms has great potential for detection of thyroid cancer at the molecular level. © 2014 Astro Ltd.


Chen G.,Fujian Medical University | Chen G.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | Chen Y.,Fujian Medical University | Zheng X.,Fujian Medical University | And 5 more authors.
Applied Physics B: Lasers and Optics | Year: 2013

In this work, we developed a SERS platform for quantitative detection of carcinoembryonic antigen (CEA) in serum of patients with colorectal cancers. Anti-CEA-functionalized 4-mercaptobenzoic acid-labeled Au/Ag core-shell bimetallic nanoparticles were prepared first and then used to analyze CEA antigen solutions of different concentrations. A calibration curve was established in the range from 5 × 10-3 to 5 × 10 5 ng/mL. Finally, this new SERS probe was applied for quantitative detection of CEA in serum obtained from 26 colorectal cancer patients according to the calibration curve. The results were in good agreement with that obtained by electrochemical luminescence method, suggesting that SERS immunoassay has high sensitivity and specificity for CEA detection in serum. A detection limit of 5 pg/ml was achieved. This study demonstrated the feasibility and great potential for developing this new technology into a clinical tool for analysis of tumor markers in the blood. © 2013 Springer-Verlag Berlin Heidelberg.


Tang W.,Fujian Medical University | Wang C.,Fujian Medical University | Chen Q.,Fujian Medical University | Chen Q.,Fujian Provincial Key Laboratory of Translational Cancer Medicine
International Journal of Molecular Medicine | Year: 2014

Mutation analysis in breast cancer has failed to explain the inactivation of RhoBTB2, a candidate breast cancer tumor suppressor gene on chromosome 8p. Some breast cancer-related genes in this region become inactivated by hypermethylation, and hypermethylation of RhoBTB2 abrogates its expression in bladder cancers. The aim of the present study was to determine whether RhoBTB2 was silenced by methylation in breast cancer. Nested methylation-specific PCR (nMSP) and quantitative reverse transcription PCR were used to analyze the methylation status and mRNA levels of RhoBTB2 in 50 paired breast cancer and normal tissues and the results were correlated with clinicopathological characteristics. Promoter methylation and the downregulation of RhoBTB2 mRNA was observed in tumor tissues (P>0.001). mRNA levels were decreased in samples with methylation (?2 = 15.751, P>0.001). RhoBTB2 methylation was observed preferentially in progesterone receptor (PR)-negative samples (P>0.05). The results demonstrated that aberrant methylation of RhoBTB2 may be responsible for the suppression of RhoBTB2 mRNA expression in breast cancer, a signifi cant event during the genesis of breast cancer that correlated with PR status.


Lin S.,Fujian Medical University | Lin S.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | Pan J.,Fujian Medical University | Pan J.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | And 9 more authors.
Radiotherapy and Oncology | Year: 2014

Background and purpose To establish the minimally required margins in different directions measured from GTV in the definitive treatment of nasopharyngeal carcinoma (NPC) using IMRT based on the 5-year results. Methods and materials Between November 2003 and May 2007, 414 patients with non-metastatic NPC were treated with IMRT according to our institutional protocol. Treatment outcomes at 5 years were analyzed. Distances from GTV-T to CTV2 (i.e., CTV 59.4 Gy) in 6 directions (anterior, posterior, superior, inferior, and bilateral) were measured and analyzed. Results The 5-year estimated overall survival (OS), disease free survival (DFS), local control (LC) were 80%, 77% and 95%, respectively. For the margins measured from GTV-T to CTV2, margins used with T4 disease were significantly and uniformly smaller than the whole group in all the 6 directions (P = 0.000, 0.000, 0.000, 0.000 and 0.046, respectively). However, no increase of local recurrence was associated to this limited margins used. Conclusions Our 5-years' experience showed a very high LC rate. The strategy we used for CTV delineation was safe and reliable. Determined CTV through GTV expansion to a minimally required margin, using GTV + margin (used in our T4 patients) + the whole nasopharyngeal mucosa, especially for the patients with early T disease, might be feasible. © 2013 Elsevier Ireland Ltd. All rights reserved.


Hong J.,Fujian Medical University | Yao Y.,Fujian Cancer Hospital | Zhang Y.,Fujian Medical University | Tang T.,Fujian Medical University | And 5 more authors.
Otolaryngology - Head and Neck Surgery (United States) | Year: 2013

Objective. The effectiveness of radiotherapy in nasopharyngeal carcinoma (NPC) is closely related to the radiosensitivity of the carcinoma; however, there is currently no effective method to predict radiosensitivity in NPC. We explored the predictive value of magnetic resonance diffusion-weighted imaging (MR-DWI) for radiosensitivity in NPC. Study Design. Prospective cohort study. Setting. Single hospital. Subjects and Methods. Patients with NPC who received intensity-modulated radiotherapy (IMRT) with or without chemotherapy were enrolled from April 2010 through November 2011. Primary tumor apparent diffusion coefficient (ADC) was measured before treatment (ADC0) and 2 weeks after the start of IMRT (ADC1). ADC change (DADC) was calculated as (ADC1 - ADC0)/ADC0*100%. Three months after the end of radiotherapy, the short-term effect of radiotherapy was assessed using the World Health Organization's response evaluation criteria in solid tumors. Results. Of 134 eligible NPC patients, 121 received combination chemotherapy. Three months after radiotherapy, residual local tumors were detected in 23 (17.2%) cases, and no residual tumors were detected in 111 (82.8%) cases. There was no significant difference in the residual tumor rates of patients receiving combination chemotherapy vs those who did not (P = 1.000). There were no significant differences in the ADC0 or ADC1 values of patients with and without residual tumors (P = .083 and .262). The DADC values of patients with (49.77% ± 31.02%) and without (68.35% ± 34.22%) residual tumors were significantly different (t = 22.406, P = .017). Logistic regression analysis indicated that DADC was an independent prognostic factor for the short-term effect of IMRT in NPC. Conclusion. Magnetic resonance diffusion-weighted imaging may potentially have value for predicting radiosensitivity in NPC. © American Academy of Otolaryngology - Head and Neck Surgery Foundation 2013.


Lin G.,Fujian Medical University | Tang Z.,Fujian Provincial Cancer Hospital | Tang Z.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | Ye Y.-B.,Fujian Medical University | And 4 more authors.
Oncology Reports | Year: 2012

The relationship between KRAS and NF-κB in colorectal cancer is not clear. Western blotting was used to determine whether KRAS knockdown in SW620 cells altered the levels of NF-κB-p65 and other molecules. Furthermore, we investigated the association between the KRAS status and NF-κB expression in 167 colorectal cancers tumor tissues and their correlation with overall survival (OS) of patients with KRAS mutations and activated NF-κB. RAS, p-ERK, p-IκBα and p65 expression was decreased in SW620 cells with KRAS knockdown. The MEK inhibitor U0126 downregulated p-ERK, p-IκBα and p65 levels in SW620 cells. p65 activation in tumors with KRAS mutations was higher (50.8%) than in tumors with the wild-type KRAS gene (30.6%) (P=0.012). Compared to patients with other types of tumors, OS was lower (median 28.4 months) in patients with KRAS mutations and NF-κB activation, vs. a median of 46.3 months in patients with other types of tumors (P=0.005). NF-κB activation was reduced in SW620 cells with KRAS knockdown, possibly via the RAS-ERK-IκBα pathway. The presence of both KRAS mutations and the active form of NF-κB in CRC tumors indicates poor patient prognosis.


Shi Y.,Fujian Medical University | Shi Y.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | Huang A.,Fujian Medical University
Tumor Biology | Year: 2015

Many patients with advanced hepatocellular carcinoma (HCC) develop lung metastasis and available treatments are limited. The anticancer drug sorafenib has opened a window of hope for patients with advanced hepatocellular carcinoma. However, the effect of sorafenib is limited by drug resistance. MicroRNAs have been reported to play an important role in HCC, but the effect of sorafenib on microRNAs (miRNAs) and on lung metastasis is not clear. This report employed a high-throughput deep sequencing technique to detect the difference of miRNAs and immunohistochemical technique to detect the difference of protein in implanted primary tumors and in metastatic HCC tumors after treatment with sorafenib. Among the detected miRNAs, we identified rno-miR-122-3p and rmo-miR-122-5p that were downregulated and rno-miR-383-5p and rno-miR-34a-5p that were upregulated and one novel miRNAs is reported as downregulated here for the first time. Immunohistochemical analysis of known miRNAs identified CMYC protein expression as inhibited, MDM2 protein was expressed, and NM23 and GST protein were upregulated. A Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of novel miRNA found that the targeted genes were concentrated in pathways of metabolism, especially in cytochrome P450. These results indicate that these miRNAs are likely to be involved in the treatment response of lung metastases of HCC to sorafenib. They may be useful as biomarkers to predict the clinical treatment response of sorafenib. © 2015, International Society of Oncology and BioMarkers (ISOBM).


Tang W.,Fujian Medical University | Su G.,Fujian Medical University | Su G.,Fujian Provincial Cancer Hospital | Li J.,Fujian Medical University | And 10 more authors.
International Journal of Oncology | Year: 2014

Upregulation of nuclear factor-κB (NF-κB) in colorectal carcinoma (CRC) accelerates tumor growth, whereas, irinotecan (CPT-11)-induced NF-κB activation reduces chemosensitivity and weakens the anti-colorectal cancer function itself, while proteasome inhibitors can inhibit NF-κB and improve the effect of chemotherapy. Carfilzomib (CFZ) is a novel proteasome inhibitor that has been recently approved by the FDA and is in clinical use for the treatment of multiple myeloma, but little is known about its activity against CRC. The aim of the present study was to explore whether CFZ alone or in combination with CPT-11 is effective in CRC treatment. We evaluated the novel therapeutic ability and mechanism of action of CFZ in CRC in vitro and in vivo. SW620 cells were incubated with CFZ alone or in combination with CPT-11. Cell proliferation was assessed by WST-1 and clonogenic assays, the cytotoxic interaction was assessed with a combination index (CI). Cell cycle progression was analysed with flow cytometry. Cell apoptosis was evaluated by detecting the Annexin V/propidium iodide (PI) ratio, caspase 3 and CD95 expression, and with TUNEL staining. Cell migration and invasion was determined with a wound-healing assay and a Transwell matrix penetration assay. A CRC xenograft model was established to monitor tumor growth. EMSA was used to analyse NF-κB activation and western blot analysis was used to detect the protein levels of related signaling factors. CFZ significantly inhibited the growth of SW620 cells, and had synergistic inhibitory effects with CPT-11 on survival and colony formation; possibly by inhibition of NF-κB activation, MEK/ERK and PI3K/AKT pathway factor dephosphorylation and survivin downregulation. Co-administration of CFZ and CPT-11 induced G2/M arrest, increased p21 WAF1/CIP, and decreased mutant p53 and cdc25c expression. Induction of apoptosis was accompanied by marked increases in PARP cleavage, caspase 3 activation, an increase of CD95 and p-p38, and ATF3 activation. Combination treatment lowered the invasive and migration ability of SW620 cells, reduced MMP and increased TIMP protein expression. Finally, co-administration of CFZ and CPT-11 suppressed tumor growth and increased apoptosis compared with single-agent treatment in SW620 xenograft models correlated with NF-κB downregulation. Carfilzomib alone or in combination with CPT-11 is effective against colorectal cancer through inhibition of multiple mechanisms related to NF-κB, and could be a potential novel therapy for CRC.


Lin S.,Fujian Provincial Cancer Hospital | Lin S.,Fujian Medical University | Lin S.,Fujian Provincial Key Laboratory of Translational Cancer Medicine | Guo Q.,Fujian Provincial Cancer Hospital | And 17 more authors.
Journal of Experimental and Clinical Cancer Research | Year: 2014

Background: Stanniocalcin 2 (STC2) is overexpressed in several types of human cancers, and its overexpression positively correlates to tumor progression and poor prognosis. However, the clinical significance of STC2 overexpression in nasopharyngeal carcinomas (NPC) has not been investigated. This study examined STC2 expression in a cohort of 94 NPC samples, and explored its value in clinical diagnosis and prognosis. Methods. Tumor samples from 94 patients diagnosed in 2008 were studied. All samples were obtained prior to treatment start. All cases were clinically diagnosed and pathologically confirmed to be poorly differentiated or undifferentiated NPC without distant metastasis, and have been treated with radical radiation therapy and followed-up for five years. Survival analyses were performed. Results: Of the 94 NPC samples, STC2 overexpression (STC2+) was detected in 65 samples (69.1%). Overall survival rate of STC2 (+) patients is significantly lower than that of patients with normal STC2 levels (72.2% vs. 96.4%, respectively, P = 0.049). Moreover, STC2 (+) is also strongly predictive of a low progression-free survival and distant metastasis-free survival (63.0% vs 92.9%. P = 0.007; and 77.0% vs 96.4%. P = 0.028). Of the 54 patients treated with IMRT, residual tumors were found in 54.8% of STC2 positive patients (17/31), but only in 17.4% of STC2 negative ones (4/23), suggesting STC2 overexpression predicts a higher risk of residual tumors after IMRT. Conclusions: STC2 overexpression correlates to poor prognosis for NPC and may be useful as a novel biomarker to predict NPC responses to radiation. Whether STC2 promotes NPC progression and metastasis remains to be investigated. © 2014 Lin et al.; licensee BioMed Central Ltd.

Loading Fujian Provincial Key Laboratory of Translational Cancer Medicine collaborators
Loading Fujian Provincial Key Laboratory of Translational Cancer Medicine collaborators